相关实验视频

Updated: Jul 25, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

优化IFN阿尔法疗法对抗骨髓增殖新生体

Gurvan Hermange¹, Paul-Henry Cournède², Isabelle Plo²

¹Université Paris-Saclay, CentraleSupélec, Laboratory of Mathematics and Informatics (MICS), Gif-sur-Yvette, France (G.H., P.-H.C.); INSERM U1287, Villejuif, France (I.P.); Gustave Roussy, Villejuif, France (I.P.); and Université Paris-Saclay, Villejuif, France (I.P.).

The Journal of pharmacology and experimental therapeutics

|June 30, 2023

概括

数学模型有助于个性化干扰素α (IFNα) 治疗骨髓增殖性瘤 (MPNs). 一定剂量策略允许更快的中断,平衡疗效与毒性,以改善MPN患者的长期结果.

科学领域:

血液学血液学血液学
数学瘤学数学瘤学
药理动力学是什么药理动力学

背景情况:

骨髓增殖性瘤 (MPNs) 是由干细胞驱动的血液癌症,其特点是血液细胞的过度生产.
在MPN中,JAK2突变是最常见的驱动因素,导致血栓的风险增加.
干扰素α (IFNα) 通过诱导血液学和分子反应,在治疗MPN方面表现有前途.

研究的目的:

使用数学建模,为MPN患者开发个性化的治疗策略.
预测患者的细胞动态,并评估不同的IFNα剂量方案.
根据反应和毒性来确定治疗中断的最佳时间.

主要方法:

使用临床数据对现有数学模型进行校准,以预测患者细胞动态.
模拟了三名MPN患者的in silico治疗场景,并结合了剂量毒性关系.
根据患者的反应,年龄和恶性克隆的演变,评估治疗中断标准.

主要成果:

一个恒定的IFNα剂量策略允许更早地中止治疗,尽管更高的剂量会增加毒性.
即使没有精确的剂量毒性知识,也可以确定个性化的权衡策略.
一个妥协策略建议在10-15年内使用中等剂量的IFNα (60-120μg/周).

结论:

数学模型,当与真实数据校准时,可以创建用于优化MPN治疗的临床决策支持工具.
这种方法为MPN患者提供了更个性化和合理的长期IFNα治疗策略.
需要对剂量毒性进行进一步的研究,以改进最佳的治疗中断时间.

更多相关视频

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...